CYP1A1 and breast cancer: Altogether, our study demonstrated the successful development of pentyl-bearing PAIB-SOs in mice, as new CYP1A1-dependent prodrugs for BC treatments that efficiently decrease BC tumor growth and show no side effects at their pharmacological concentration.